Asaf Zviran

Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

The New York City Investment Fund Manager Inc. (The New York City Investment Fund Manager) is a venture capital firm founded by Henry Kravis in 1996. The firm is headquartered in New York, United States.

GBooking Ltd. develops and provides online appointment scheduling software solutions. It provides small and medium-sized businesses with web-based online promotion and advertising tools. The company was founded by Alexander Naslednikov, Liran Gavish, Alexander Bryzgalov, Ronen Kagan and Fadi Karkaby in 2010 and is headquartered in Haifa, Israel.

Casdin Capital LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Eli Casdin in 2012. They provide investment management services to pooled investment vehicle, or more specifically, a private investment fund, the securities of which are offered to certain qualified investors on a private placement basis.

Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD.

Genome Compiler Israel Ltd. develops software for personalized synthetic genome design. It provides an intuitive all-in-one software platform for genetic engineers, molecular and synthetic biologists. The company was founded by Omri Amirav-Drory Nir Ben Moshe, Yogev Debbi and Roy Nevo in 2011 and is headquartered in Tel Aviv, Israel.

Imagen Technologies, Inc. operates as a medical technology company that develops and offers devices for the prevention of diagnostic errors. The company was founded by Alexander Dresner, Robert Lindsey, Thomas Stuart Hotchkiss and Sumit Chopra in 2015 and is headquartered in New York, NY.

NFX Capital Management LLC (NFX Capital) is a venture capital firm founded in 2015. The firm is headquartered in San Francisco, California.

Casdin Capital /Private Equity/ (Casdin Capital) is a private equity/venture capital subsidiary of Casdin Capital LLC founded in 2012 by Eli Casdin. The firm is headquartered in New York.

Genome Medical Holding Co. operates tele genomics platform which allows genetic experts to consult with patients and physicians across the country. The firm specializes in genomics, genetics, precision medicine, medical practice, personalized medicine, genetic counseling, DNA and genome. The company was founded by Lisa J. Alderson, Robert C. Green and Randal W. Scott in 2016 and is headquartered in South San Francisco, CA.

Metabiotech Corp. operates a platform technology for reading and fixing DNA. Its synthetic biology solutions accelerate the design-build-test cycle for biotechnology and bioengineering and genomics pipeline that discovers clinically actionable genetic information for human diseases. The company was founded by Tuval Ben-Yehezkel and is headquartered in San Jose, CA.

Cedilla Therapeutics, Inc. operats as a biotechnology company. It engages in discovering and exploiting insights into protein stability. The company was founded by Alan D. D?Andrea, Steve Gygi, Matthew P. Jacobson, William G. Kaelin, Jr. and Jack Taunton on September 6, 2017 and is headquartered in Cambridge, MA.

Mammoth Biosciences, Inc. operates CRISPR-based platform for disease detection. The firm offers its services under the categories of bioinformatics, biotechnology, genetics, health diagnostics and life science. The company was founded by Ashley Tehranchi, Janice Chen, Jennifer A. Doudna, Lucas Harrington and Trevor Martin and is headquartered in South San Francisco, CA.

Omri AD Tech.Bio Ltd. was founded by Omri Amirav-Drory on September 17, 2019 and is headquartered in Herzliya, Israel.

Prominex, Inc. manufactures molecular diagnostic assays for infectious disease testing. The company was founded by Paul Thomas and Paul Gargan in 2017 and is headquartered in San Diego, CA.

Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation.

Immunai, Inc. engages in decoding of immune system to improve health. It offers an immune profiling platform, which is used to advance research and development in checkpoint blockade, cancer cell therapy, and cancer vaccines. The company was founded by Noam Solomon, Luis Voloch, Danny Wells, Ansuman Satpathy and Dan R. Littman in December 2018 and is headquartered in New York, NY.

Light Bio, Inc. engages in other technology industry. The company is headquartered in Mount Horeb, WI.

GeneMatters LLC operates as a digital technology platform that provides genomic medicine delivery services. The company is based in Minneapolis, MN.

Wild Biotech Ltd. develops a drug discovery platform. The private company is based in Rehovot, Israel. The Israeli company was founded by Ido Bachelet, Neta Raab, and Doron Levin. The CEO is Neta Raab.

Pangea Therapeutics Ltd. is an Israeli company that specializes in developing a proprietary tumor intelligence platform called Technology Enlight. The company is based in Tel Aviv, Israel. This platform enables a deeper understanding of how a tumor would respond to therapy by considering expression abnormalities, which are more common than actionable mutations. By combining these with tumor vulnerability maps, the platform uncovers many more clinically relevant insights than approaches based solely on genomic alterations. The company was founded by Eytan Ruppin, Eyal Gottlieb, Ze'ev Ronai. The CEO is Tuvik Beker.

Talus Bioscience, Inc. is a company that aims to address the primary cause of cancer and other diseases, which is regulome dysfunction. The company is based in Seattle, WA, and recently raised 9.75 million in seed funding to support their efforts. The company is focused on developing a drug discovery platform that can rapidly measure and manipulate the regulome, providing a new approach to cancer therapeutics. The company has also hired a new COO, Michelle Briscoe. Talus Bioscience was founded by Alex Federation and Lindsay Pino, with Alex Federation serving as CEO since incorporation.

Pepper Bio, Inc. develops an AI-based drug discovery platform. The American company was founded by Samantha Dale Strasser and Yu Jon Hu, with Yu Jon Hu serving as the CEO since incorporation.

Gilboa Therapeutics Ltd. is a preclinical-stage biopharmaceutical company located in Israel. The Israeli company is focused on developing novel and high-impact, next-generation cancer immunotherapies that harness the power of a patient's own immune system to treat cancer, improve outcomes, and save lives. Gilboa's proprietary technology, solidt, is an engineered cell therapy that targets multiple different tumor types and is intended to be used in combination with a wide range of antigen-specific antibodies. The company is driven by a sense of urgency to discover, develop, and rapidly bring their game-changing new therapeutics to cancer patients in need, significantly improving outcomes and saving lives.

Nanocarry Therapeutics Ltd. is a company based in Nes-Ziona, Israel. Nanocarry is developing a new class of therapeutics using bioengineered nanoparticles to treat oncology indications and brain diseases. The Israeli company's proprietary "plug and play" approach allows for easy modification to deliver a wide array of biologics safely and effectively to the brain and beyond. Nanocarry's first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer. The company aims to extend the reach of biological therapeutics to the brain to tackle CNS diseases head-on, pioneering a multidisciplinary approach that overcomes the blood-brain barrier. The company was founded by Rachela Popovtzer, Oshra Betzer, and Revital Mandil-Levin, with Revital Mandil-Levin serving as the CEO since incorporation.

La Jolla Labs, Inc. is a company that utilizes RNA biology, automation, cloud computing, and machine learning to provide innovative medical solutions to patients. The company is based in La Jolla, CA. The company specializes in various RNA-targeting modalities, such as splicing gapmers, miRNA, antisense oligonucleotides, and siRNA. The CEO of the company is Donald Jeff Milton.

Eleven Therapeutics Ltd. is an Israeli biotech company that combines artificial intelligence, functional assays, and combinatorial chemistry to develop RNAi therapeutics. The company was founded in 2020 by a group of interdisciplinary scientists and has three collaborative hubs located in undisclosed locations. The company is based in an undisclosed location. Eleven Therapeutics is currently focused on developing siRNA treatments for respiratory diseases using its flagship invention, SCSI-RNA™. This fully programmable molecule is designed to address the delivery, durability, and efficacy challenges of any disease and biological target of interest. The company was founded by Erlich Yaniv, Shaun Ilan, Greg Hannon, and Erlich Yaniv has been the CEO since incorporation.

Mana.Bio operates as an AI based drug delivery company. The company was founded by Yogev Debbi and Roy Nevo and is headquartered in United States.

Leyden Labs develops preventive medicines that target respiratory viruses. The private company is based in Leiden, Netherlands.

ResistanceBio, Inc. is a company that focuses on overcoming treatment-resistant cancer. The company is based in San Carlos, CA. The company's mission is to defeat this type of cancer by developing a novel class of multi-targeted oncology treatments called Resistance Suppressing Therapy (REST). ResistanceBio was founded by Nicholas Goldner and Christopher Bulow, with Nicholas Goldner serving as the CEO since incorporation.

IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation.